12:00 AM
 | 
Jun 18, 2001
 |  BioCentury  |  Finance

Analyst picks & changes

Dendreon Corp. (DNDN), Seattle, Wash.

Business: Cancer

Needham & Co. analyst Mark Monane raised his price target to $18-$20 from...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >